Eleventh Five Year Plan

Health and Family Welfare and AYUSH 113Educational Institutions3.2.19 National Institutes of various AYUSH systemshave been set up by the Central Government to setbenchmarks for teaching, research, and clinical practices.Keeping in view the need for upgrading thesenational institutes into Centres of Excellence, a substantialincrease in outlay will be made in the EleventhFive Year Plan. This increase is also on account of settingup a state-of-the-art tertiary Ayurveda centre inthe national capital with R&D focus and tertiary healthcare facilities.3.2.20 Most of the AYUSH undergraduate and postgraduatecolleges in the government sector sufferfrom a variety of infrastructure constraints. As lowquality of AYUSH education is one of the crucialfactors for lack of public confidence in AYUSHsystem, selected institutions in governmental andnon-governmental sector having better track recordswill be upgraded into Centres of Excellence. Anincreased outlay will be provided to ensure that AYUSHinstitutions are brought up to the minimum standardsprescribed by the Statutory Body within the EleventhFive Year Plan period.Research and Development (R&D)3.2.21 The infrastructure and capacities of AYUSHresearch councils will be upgraded to enable them tocarry out state-of-the-art scientific work related todrug standardization and quality control, botanicalstandardization, laying down of pharmacopoeial standards,and clinical trials.3.2.22 Golden Triangle Research partnership initiatedby Department of AYUSH with collaboration ofCCRAS, ICMR, and CSIR is aimed at scientific validationand development of R&D based drugs as wellas development of herbal drugs based on traditionalmedicinal knowledge for prioritized disease conditions.Ayurveda, Siddha, Unani, and Homoeopathy drugindustry is being associated with this initiative. Forexpediting the work of laying down pharmacopoeialstandards of single drugs and poly-herbal formulations,the research councils have been declared asthe Secretariats of the Pharma-copoeias Committees.Various peripheral units/laboratories of research councilswill be upgraded for undertaking sophisticatedscientific work relating to development of marker compoundsand biologically active ingredients for drugstandardization and development.Medicinal Flora and Fauna3.2.23 The NMPB is functioning with a very smallcomponent of staff as an extension of the Department.Manifold increase in outlay for the Eleventh Five YearPlan is to restructure the NMPB as an autonomousbody and provide sufficient manpower to undertakeits wide mandate. A Centrally Sponsored componentfor cultivation, processing, and marketing of medicinalplants is being started from the outlay of NMPB.This will have sub components for financial allocation:cultivation of prioritized medicinal plants speciesover 75000 hectares; raising of 50 lakh seedlings;setting up of Centralized Seed Centre and Nursery forcultivating planting materials for 15 States; setting upof six medicinal plants zones in agro-climatic zonesof the country; and market development assistancefund for plan building and marketing support. Anotherexisting Central Sector component is regardingprogramme for in-situ conservation, creation of GeneBank for medicinal plants, ex-situ conservation ofprioritized medicinal plants, R&D for quality standards,and certification and programme for IEC.Hospitals and Dispensaries3.2.24 This Scheme has now been subsumed underthe NRHM, as it aims at creating AYUSH facilities inPHCs, CHCs, and district hospitals for the purpose ofmainstreaming of AYUSH under NRHM. The ambitof the scheme is widened to provide support forstrengthening of AYUSH dispensaries, hospitals andfor supply of AYUSH medicinal kits in rural areasand for development of specialized AYUSH treatmentcentres under PPP mode.Industry3.2.25 AYUSH industry at present suffers from smallscale of operation and low technology that needs tobe upgraded. Majority of the 5000 GMP compliancemanufacturing units are of small and medium size.Even though back ended subsidy to these units underthe Centrally sponsored component ‘Drug Quality